Email Us Here

Creative BioTherapeutics Named 2026 Prix Galien USA Best Startup Nominee for Work Advancing CBT300

Recognition marks a new chapter for the oncology-focused biotechnology company as it continues development of its investigational biologic candidate targeting mechanisms associated with cancer recurrence and treatment resistance.